nach oben

Head and Neck Pathology

Erschienen in:

01.12.2024 | Review

Proceedings of the 2024 North American Society of Head and Neck Pathology Companion Meeting, Baltimore, MD, March 24, 2024: Navigating Ancillary Studies in Basaloid/Blue Salivary Tumors

verfasst von: Kristine S. Wong

Erschienen in: Head and Neck Pathology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Basaloid salivary tumors can demonstrate significant morphologic overlap and be challenging to diagnose.

Methods

A review of select ancillary studies in basaloid salivary tumors was performed.

Results

A number of immunohistochemical stains, including PLAG1, HMGA2, β-catenin, MYB, and RAS Q61R, have been more recently incorporated into the diagnostic workup of basaloid salivary tumors.

Conclusions

Although reported variability in their performance has perhaps limited their widespread adoption, these immunohistochemical studies can nevertheless be useful in supporting pathologic diagnoses, particularly when considered in more specific differentials or when used as a panel with other markers.

Kong M, Drill EN, Morris L, et al. Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands A Clinicopathologic Study of 48 Cases. Published online 2015. www.ajsp.com

Xu B, Mneimneh W, Torrence DE et al (2019) Misinterpreted myoepithelial carcinoma of salivary gland: a challenging and potentially significant pitfall. Am J Surg Pathol 43(5):601–609. https://doi.org/10.1097/PAS.0000000000001218CrossRefPubMedPubMedCentral

Xu B, Katabi N (2021) Myoepithelial carcinoma. Surg Pathol Clin 14(1):67–73. https://doi.org/10.1016/j.path.2020.09.008CrossRefPubMedPubMedCentral

Dalin MG, Katabi N, Persson M et al (2017) Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun. https://doi.org/10.1038/s41467-017-01178-zCrossRefPubMedPubMedCentral

Katabi N, Ghossein R, Ho A et al (2015) Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol 46(1):26–33. https://doi.org/10.1016/j.humpath.2014.08.017CrossRefPubMed

Bahrami A, Dalton JD, Shivakumar B, Krane JF (2012) PLAG1 Alteration in carcinoma ex pleomorphic adenoma: immunohistochemical and fluorescence in situ hybridization studies of 22 cases. Head Neck Pathol 6(3):328–335. https://doi.org/10.1007/s12105-012-0353-8CrossRefPubMedPubMedCentral

Martins C, Fonseca I, Roque L et al (2005) PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma: a combined study using chromosome banding, in situ hybridization and immunocytochemistry. Mod Pathol 18(8):1048–1055. https://doi.org/10.1038/modpathol.3800386CrossRefPubMed

Kas K, Voz ML, Röijer E et al (1997) Promoter swapping between the genes for a novel zinc finger protein and β-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 15(2):170–174. https://doi.org/10.1038/ng0297-170CrossRefPubMed

Geurts JMW, Schoenmakers EFPM, Röijer E, Aström AK, Stenman G, Van De Ven WJM (1998) Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16(7):865–872. https://doi.org/10.1038/sj.onc.1201609CrossRefPubMed

10.

Persson F, Andrén Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer 48(1):69–82. https://doi.org/10.1002/gcc.20619CrossRefPubMed

11.

Katabi N, Xu B, Jungbluth AA et al (2018) PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities. Histopathology 72(2):285–293. https://doi.org/10.1111/his.13341CrossRefPubMed

12.

de Brito BS, Giovanelli N, Egal ES et al (2016) Loss expression of Plag1 in malignant transformation from pleomorphic adenoma to carcinoma ex pleomorphic adenoma. Hum Pathol 57:152–159. https://doi.org/10.1016/j.humpath.2016.07.011CrossRefPubMed

13.

Xu B, Barbieri AL, Bishop JA et al (2020) Histologic classification and molecular signature of polymorphous adenocarcinoma (PAC) and cribriform adenocarcinoma of salivary gland (CASG) an international interobserver study. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001431CrossRefPubMedPubMedCentral

14.

Nonaka T, Takei H (2022) Immunohistochemical profile of polymorphous adenocarcinoma of minor salivary gland: a systematic review and meta-analysis. Head Neck Pathol 16(4):980–990. https://doi.org/10.1007/s12105-022-01453-6CrossRefPubMedPubMedCentral

15.

Ohtomo R, Mori T, Shibata S et al (2013) SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol 26(8):1041–1050. https://doi.org/10.1038/modpathol.2013.54CrossRefPubMed

16.

Adkins BD, Geromes A, Zhang LY et al (2020) SOX10 and GATA3 in adenoid cystic carcinoma and polymorphous adenocarcinoma. Head Neck Pathol 14(2):406–411. https://doi.org/10.1007/s12105-019-01046-wCrossRefPubMed

17.

Gnepp D, Chen J, Warren C (1988) Polymorphous low-grade adenocarcinoma of minor salivary gland. An immunohistochemical and clinicopathologic study. Am J Surg Pathol 12(6):461–468CrossRefPubMed

18.

Regezi JA, Zarbo RJ, Stewart JCB, Courtney R, Arbor A, Detroit M (1991) Polymorphous low-grade adenocarcinoma of minor salivary gland a comparative histologic and immunohistochemical study. Oral Surg Oral Med Oral Pathol 71(4):469–475CrossRefPubMed

19.

Castle JT, Thompson LDR, Frommelt RA, Wenig BM, Kessler HP (1999) Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 86(2):207–219. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2%3c207::AID-CNCR4%3e3.0.CO;2-QCrossRefPubMed

20.

Owosho AA, Aguilar CE, Seethala RR (2016) Comparison of p63 and p40 (ΔNp63) as basal, squamoid, and myoepithelial markers in salivary gland tumors. Appl Immunohistochem Mol Morphol 24(7):501–508CrossRefPubMed

21.

Rooper L, Sharma R, Bishop JA (2015) Polymorphous low grade adenocarcinoma has a consistent p63+/p40− immunophenotype that helps distinguish it from adenoid cystic carcinoma and cellular pleomorphic adenoma. Head Neck Pathol 9(1):79–84. https://doi.org/10.1007/s12105-014-0554-4CrossRefPubMed

22.

Xu B, Aneja A, Ghossein R, Katabi N (2016) Predictors of outcome in the phenotypic spectrum of polymorphous low-grade adenocarcinoma (PLGA) and cribriform adenocarcinoma of salivary gland (CASG) a retrospective study of 69 patients. Am J Surg Pathol 40(11):1526–1537CrossRefPubMedPubMedCentral

23.

Bishop JA, Sajed DP, Weinreb I et al (2021) Microsecretory adenocarcinoma of salivary glands: an expanded series of 24 cases. Head Neck Pathol 15(4):1192–1201. https://doi.org/10.1007/s12105-021-01331-7CrossRefPubMedPubMedCentral

24.

Matsuyama A, Hisaoka M, Nagao Y, Hashimoto H (2011) Aberrant PLAG1 expression in pleomorphic adenomas of the salivary gland: a molecular genetic and immunohistochemical study. Virchows Arch 458(5):583–592. https://doi.org/10.1007/s00428-011-1063-4CrossRefPubMed

25.

Rotellini M, Palomba A, Baroni G, Franchi A (2014) Diagnostic utility of PLAG1 immunohistochemical determination in salivary gland tumors. Appl Immunohistochem Mol Morphol 22(5):390–394. https://doi.org/10.1097/PAI.0b013e3182936ea7CrossRefPubMed

26.

Lee JH, Kang HJ, Yoo CW et al (2019) PLAG1, SOX10, and Myb expression in benign and malignant salivary gland neoplasms. J Pathol Transl Med 53(1):23–30. https://doi.org/10.4132/jptm.2018.10.12CrossRefPubMed

27.

Weinreb I, Zhang L, Tirunagari LMS et al (2014) Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer 53(10):845–856. https://doi.org/10.1002/gcc.22195CrossRefPubMed

28.

Weinreb I, Piscuoglio S, Martelotto LG et al (2014) Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 46(11):1166–1169. https://doi.org/10.1038/ng.3096CrossRefPubMedPubMedCentral

29.

Hahn E, Xu B, Katabi N et al (2023) Comprehensive molecular characterization of polymorphous adenocarcinoma, cribriform subtype: identifying novel fusions and fusion partners. Mod Pathol 36(11):100305. https://doi.org/10.1016/j.modpat.2023.100305CrossRefPubMed

30.

Foo WC, Jo VY, Krane JF (2016) Usefulness of translocation-associated immunohistochemical stains in the fine-needle aspiration diagnosis of salivary gland neoplasms. Cancer Cytopathol 124(6):397–405. https://doi.org/10.1002/cncy.21693CrossRefPubMed

31.

Avadhani V, Cohen C, Siddiqui MT (2016) PLAG1: an immunohistochemical marker with limited utility in separating pleomorphic adenoma from other basaloid salivary gland tumors. Acta Cytol 60(3):240–245. https://doi.org/10.1159/000447622CrossRefPubMed

32.

Mito JK, Jo VY, Chiosea SI, Dal Cin P, Krane JF (2017) HMGA2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma ex-pleomorphic adenoma. Histopathology 71(4):511–521. https://doi.org/10.1111/his.13246CrossRefPubMed

33.

Kawahara A, Harada H, Abe H et al (2011) Nuclear β-catenin expression in basal cell adenomas of salivary gland. J Oral Pathol Med 40(6):460–466. https://doi.org/10.1111/j.1600-0714.2011.01010.xCrossRefPubMed

34.

Jo VY, Sholl LM, Krane JF (2016) Distinctive patterns of CTNNB1 (β-Catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma. Am J Surg Pathol 40(8):1143–1150. https://doi.org/10.1097/PAS.0000000000000669CrossRefPubMed

35.

Lee YH, Huang WC, Hsieh MS (2018) CTNNB1 mutations in basal cell adenoma of the salivary gland. J Formos Med Assoc 117(10):894–901. https://doi.org/10.1016/j.jfma.2017.11.011CrossRefPubMed

36.

Sato M, Yamamoto H, Hatanaka Y et al (2018) Wnt/β-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. Pathol Res Pract 214(4):586–592. https://doi.org/10.1016/j.prp.2017.12.016CrossRefPubMed

37.

Jung MJ, Roh JL, Choi SH et al (2013) Basal cell adenocarcinoma of the salivary gland: a morphological and immunohistochemical comparison with basal cell adenoma with and without capsular invasion. Diagn Pathol. https://doi.org/10.1186/1746-1596-8-171CrossRefPubMedPubMedCentral

38.

Wilson TC, Ma D, Tilak A, Tesdahl B, Robinson RA (2016) Next-generation sequencing in salivary gland basal cell adenocarcinoma and basal cell adenoma. Head Neck Pathol 10(4):494–500. https://doi.org/10.1007/s12105-016-0730-9CrossRefPubMedPubMedCentral

39.

Yu GY, Ubmueller J, Donath K (1998) Membranous basal cell adenoma of the salivary gland: a clinicopathologic study of 12 cases. Acta Otolaryngol (Stockh) 118:588–593CrossRefPubMed

40.

Choi HR, Batsakis JG, Callender DL, Prieto VG, Luna MA, El-Naggar AK (2002) Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma? Am J Surg Pathol 26(6):778–783. https://doi.org/10.1097/00000478-200206000-00012CrossRefPubMed

41.

Kazakov DV (2016) Brooke-spiegler syndrome and phenotypic variants: an update. Head Neck Pathol 10(2):125–130. https://doi.org/10.1007/s12105-016-0705-xCrossRefPubMedPubMedCentral

42.

Rito M, Mitani Y, Bell D et al (2018) Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol 31(7):1064–1072. https://doi.org/10.1038/s41379-018-0018-6CrossRefPubMed

43.

Bilodeau EA, Acquafondata M, Barnes EL, Seethala RR (2015) A comparative analysis of LEF-1 in odontogenic and salivary tumors. Hum Pathol 46(2):255–259. https://doi.org/10.1016/j.humpath.2014.10.018CrossRefPubMed

44.

Schmitt AC, Griffith CC, Cohen C, Siddiqui MT (2017) LEF-1: Diagnostic utility in distinguishing basaloid neoplasms of the salivary gland. Diagn Cytopathol 45(12):1078–1083. https://doi.org/10.1002/dc.23820CrossRefPubMedPubMedCentral

45.

Mathew EP, Todorovic E, Truong T et al (2022) Metatypical adenoid cystic carcinoma a variant showing prominent squamous differentiation with a predilection for the sinonasal tract and skull base. Am J Surg Pathol 46(6):816–822CrossRefPubMed

46.

Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106(44):18740–18744. https://doi.org/10.1073/pnas.0909114106CrossRefPubMedPubMedCentral

47.

Persson M, Andrén Y, Moskaluk CA et al (2012) Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 51(8):805–817. https://doi.org/10.1002/gcc.21965CrossRefPubMed

48.

West RB, Kong C, Clarke N et al (2011) MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 35(1):92–99. https://doi.org/10.1097/PAS.0b013e3182002777CrossRefPubMedPubMedCentral

49.

Mitani Y, Liu B, Rao PH et al (2016) Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res 22(3):725–733. https://doi.org/10.1158/1078-0432.CCR-15-2867-TCrossRefPubMed

50.

Brayer KJ, Frerich CA, Kang H, Ness SA (2016) Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov 6(2):176–187. https://doi.org/10.1158/2159-8290.CD-15-0859CrossRefPubMed

51.

Ueda K, Murase T, Kawakita D et al (2023) The landscape of MYB/MYBL1- and Peri-MYB/MYBL1-associated rearrangements in adenoid cystic carcinoma. Mod Pathol 36(10):100274. https://doi.org/10.1016/j.modpat.2023.100274CrossRefPubMed

52.

Brill LB, Kanner WA, Fehr A et al (2011) Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 24(9):1169–1176. https://doi.org/10.1038/modpathol.2011.86CrossRefPubMed

53.

Rooper LM, Lombardo KA, Oliai BR, Ha PK, Bishop JA (2021) MYB RNA in situ hybridization facilitates sensitive and specific diagnosis of adenoid cystic carcinoma regardless of translocation status. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001616CrossRefPubMedPubMedCentral

54.

Persson M, Andersson MK, Mitani Y et al (2022) Rearrangements, expression, and clinical significance of MYB and MYBL1 in adenoid cystic carcinoma: a multi-institutional study. Cancers (Basel). https://doi.org/10.3390/cancers14153691CrossRefPubMed

55.

Xu B, Drill E, Ho A et al (2017) Predictors of outcome in adenoid cystic carcinoma of salivary glands a clinicopathologic study with correlation between MYB fusion and protein expression. Am J Surg Pathol. 41(10):1422–1432CrossRefPubMedPubMedCentral

56.

Moon A, Cohen C, Siddiqui MT (2016) MYB expression: Potential role in separating adenoid cystic carcinoma (ACC) from pleomorphic adenoma (PA). Diagn Cytopathol 44(10):799–804. https://doi.org/10.1002/dc.23551CrossRefPubMed

57.

Pusztaszeri MP, Sadow PM, Ushiku A, Bordignon P, McKee TA, Faquin WC (2014) MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens. Cancer Cytopathol 122(4):257–265. https://doi.org/10.1002/cncy.21381CrossRefPubMed

58.

Sun T, Akalin A, Dresser K, Fischer AH, Zuo T (2021) The utility of MYB immunohistochemistry (IHC) in fine needle aspiration (FNA) diagnosis of adenoid cystic carcinoma (AdCC). Head Neck Pathol 15(2):389–394. https://doi.org/10.1007/s12105-020-01202-7CrossRefPubMed

59.

Rooney SL, Robinson RA (2017) Immunohistochemical expression of MYB in salivary gland basal cell adenocarcinoma and basal cell adenoma. J Oral Pathol Med 46(9):798–802. https://doi.org/10.1111/jop.12617CrossRefPubMed

60.

Skalova A, Leivo I, Hellquist H et al (2021) High-grade transformation/dedifferentiation in salivary gland carcinomas: occurrence across subtypes and clinical significance. Adv Anat Pathol. 28(3):107–118CrossRefPubMed

61.

Nagao T, Gaffey TA, Serizawa H et al (2003) Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod Pathol 16(12):1265–1272. https://doi.org/10.1097/01.MP.0000097366.88165.08CrossRefPubMed

62.

Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, Leon BE (2007) Adenoid cystic carcinoma with high-grade transformation a report of 11 cases and a review of the literature. Am J Surg Pathol 31(11):1683–1694CrossRefPubMed

63.

Weinreb I, Rooper LM, Dickson BC et al (2023) Adenoid cystic carcinoma with striking tubular hypereosinophilia a unique pattern associated with nonparotid location and both canonical and novel EWSR1::MYB and FUS::MYB fusions. Am J Surg Pathol 47(4):497–503CrossRefPubMed

64.

Bishop JA, Westra WH (2018) MYB translocation status in salivary gland epithelial-myoepithelial carcinoma evaluation of classic, variant, and hybrid forms. Am J Surg Pathol 42(3):319–325CrossRefPubMedPubMedCentral

65.

Urano M, Nakaguro M, Yamamoto Y et al (2019) Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum. Am J Surg Pathol 43(7):984–994CrossRefPubMed

66.

El Hallani S, Udager AM, Bell D et al (2018) Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol 42(1):18–27. https://doi.org/10.1097/PAS.0000000000000933CrossRefPubMedPubMedCentral

67.

Nakaguro M, Tanigawa M, Hirai H et al (2021) The diagnostic utility of ras q61r mutation-specific immunohistochemistry in epithelial-myoepithelial carcinoma. Am J Surg Pathol 45(7):885–894CrossRefPubMedPubMedCentral

68.

Chiosea SI, Miller M, Seethala RR (2014) HRAS mutations in epithelial-myoepithelial carcinoma. Head Neck Pathol 8(2):146–150. https://doi.org/10.1007/s12105-013-0506-4CrossRefPubMed

69.

Cros J, Sbidian E, Hans S et al (2013) Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol 24(10):2624–2629. https://doi.org/10.1093/annonc/mdt338CrossRefPubMed

70.

Grünewald I, Vollbrecht C, Meinrath J et al (2015) Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 6(20):18224–18237CrossRefPubMedPubMedCentral

Titel: Proceedings of the 2024 North American Society of Head and Neck Pathology Companion Meeting, Baltimore, MD, March 24, 2024: Navigating Ancillary Studies in Basaloid/Blue Salivary Tumors
verfasst von: Kristine S. Wong
Publikationsdatum: 01.12.2024
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 1/2024
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-024-01626-5

Springer Medizin

Proceedings of the 2024 North American Society of Head and Neck Pathology Companion Meeting, Baltimore, MD, March 24, 2024: Navigating Ancillary Studies in Basaloid/Blue Salivary Tumors

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Dynamic Role of miRNAs in Salivary Gland Carcinomas: From Biomarkers to Therapeutic Targets

Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma

An Evaluation of High-Risk HPV in Squamous Cell Carcinomas of the Lip in a South African Cohort

FNA of Meningioma with Rhabdoid Features Presenting as a Lateral Neck Mass

An Update on the Use of Artificial Intelligence in Digital Pathology for Oral Epithelial Dysplasia Research

Recurrence of Glandular Odontogenic Cysts: A Systematic Review

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie